Stock Market Reviews

MIRM (Mirum Pharmaceuticals, Inc.) News

Get the latest news, insights, and market updates on MIRM (Mirum Pharmaceuticals, Inc.). Explore the news page 7 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened
  Mirum posts third-quarter profit and stronger revenues on surging Livmarli demand, while tightening its 2025 sales outlook.
  Nov 5, 2025 - $MIRM
• Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
  FOSTER CITY, Calif., November 04, 2025--Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
  Nov 4, 2025 - $MIRM
• Mirum Pharmaceuticals, Inc. (MIRM) Surpasses Q3 Earnings and Revenue Estimates
  Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of +150.00% and +0.85%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 4, 2025 - $MIRM
• Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
  FOSTER CITY, Calif., November 03, 2025--Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
  Nov 3, 2025 - $MIRM
• Techne (TECH) Reports Next Week: What to Know Ahead of the Release
  Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
  Oct 29, 2025 - $MIRM
• Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
  FOSTER CITY, Calif., October 28, 2025--Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
  Oct 28, 2025 - $MIRM
• Loss-Making Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Expected To Breakeven In The Medium-Term
  We feel now is a pretty good time to analyse Mirum Pharmaceuticals, Inc.'s ( NASDAQ:MIRM ) business as it appears the...
  Sep 21, 2025 - $MIRM
• Mirum Pharmaceuticals Announces Enrollment Completion in the Phase 2b VISTAS Study
  FOSTER CITY, Calif., September 08, 2025--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the completion of enrollment in the Phase 2b VISTAS study of volixibat, an investigational oral IBAT inhibitor, for the treatment of cholestatic pruritus in patients with primary sclerosing cholangitis (PSC). The trial previously met its pre-specified efficacy and safety thresholds at the blinded interim analysis for dose selection conducted in 2024 and topline results are expected to be announced
  Sep 8, 2025 - $MIRM
• IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies | DelveInsight
  DelveInsight's IBAT Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC), metabolic dysfunction-associated steatohepatitis (MASH), chronic constipation, biliary atresia, Alagille syndrome (ALGS), and others. The selected indications are based on app
  Aug 11, 2025 - $MIRM
• Arm initiated, Adobe downgraded: Wall Street's top analyst calls
  Arm initiated, Adobe downgraded: Wall Street's top analyst calls
  Aug 11, 2025 - $MIRM